What is OncoPep?
OncoPep, Inc. operates at the intersection of immunology and oncology, specializing in the development of targeted immunotherapeutics. The company's core technology, which is exclusively licensed, focuses on the creation of therapeutic cancer vaccines designed to prime the patient's immune system to recognize and eliminate malignant cells. By utilizing proprietary peptide combinations, OncoPep aims to provide a more effective and less toxic alternative to traditional chemotherapy and radiation treatments.
The company's market position is defined by its commitment to clinical innovation and its ability to attract high-caliber institutional and strategic partners. As the firm matures, its focus remains on validating its therapeutic candidates through clinical trials, ensuring that its peptide-based approach can be scaled to address various forms of cancer, thereby establishing a sustainable competitive advantage in the high-growth immunotherapy market.
How much funding has OncoPep raised?
OncoPep has raised a total of $28.4M across 5 funding rounds:
Angel/Seed
$4.5M
Series A
$2.5M
Private Equity
$3.5M
Series B
$6.9M
Series D
$11M
Angel/Seed (2011): $4.5M, investors not publicly disclosed
Series A (2012): $2.5M led by NewSpring Health Capital
Private Equity (2014): $3.5M supported by NewSpring Health Capital
Series B (2014): $6.9M featuring The Leukemia & Lymphoma Society
Series D (2021): $11M backed by CrystalBioScience, Tera Science, KUKJE Pharma, and SX Company
Key Investors in OncoPep
NewSpring Health Capital
NewSpring partners with companies in dynamic industries to catalyze new growth. Partnering with management teams to help develop their businesses into market leaders, NewSpring identifies opportunities and builds relationships using through it's network of industry leaders.
The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society is at the forefront of the fight to cure cancer. We are the largest nonprofit dedicated to creating a world without blood cancers. Since 1949, weve invested nearly $1.3 billion in groundbreaking research, pioneering many of todays most innovative approaches.
Tera Science
Tera Science provides cutting-edge technological solutions aimed at enhancing health and longevity, specifically for health professionals. Their product offerings include advanced tools such as digital bioimpedance, AI-generated 3D avatars, and innovative physical assessment models.
What's next for OncoPep?
With the successful closure of its recent financing round, OncoPep is well-positioned to accelerate its clinical development pipeline. The capital will likely be deployed to support ongoing trial phases, expand research capabilities, and potentially explore new therapeutic indications for its vaccine platform. As the company transitions into a more mature enterprise phase, the focus will shift toward achieving key clinical milestones that could lead to regulatory approval and commercialization.
Strategic partnerships with established pharmaceutical entities and specialized health investors will remain critical as OncoPep scales its operations. The company's ability to maintain its research momentum while navigating the complexities of late-stage clinical development will be the primary determinant of its long-term success in the competitive oncology landscape.
